Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions.
Thank
you for visiting the ASK2ME Giving Page. By allowing clinicians to enter
patient information and receive patient specific cancer risks, your
contribution to the http://ask2me.org/ tool stands to help increase the quality
of precision cancer prevention and disease management activities relying on
panel testing.
The introduction of next-generation sequencing markedly decreased the cost of
genetic testing. Now, 26 to 80 cancer susceptibility genes are routinely tested
in a variety of panels that are less costly than former single syndrome tests.
While this capability is fascinating, it requires new solutions for clinicians
to assess risk and provide actionable information to their patients.
The tool gives absolute risk based on a person's gender, age, prior surgery,
prior cancers, and genetic testing results. This assessment is made using a
knowledge base of reliable, documentable, and scientifically current data.
Dana-Farber Cancer Institute's involvement in this activity is led by Giovanni
Parmigiani, PhD, Chair of the Department of Biostatistics and Computational
Biology.
Philanthropy underpins innovation and it is what propels us toward critical
improvements in cancer diagnosis, prevention, and treatment. This project is an
example where philanthropy is of direct help to patients and clinicians today.
Thank you for your partnership in advancing our lifesaving work.